Stockreport

Spero Therapeutics Highlights SPR741 Phase 1 and Preclinical Data at the 28th European Congress of Clinical Microbiology and Infectious Diseases

Spero Therapeutics, Inc.  (SPRO) 
Last spero therapeutics, inc. earnings: 3/16 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: investors.sperotherapeutics.com/overview
PDF CAMBRIDGE, Mass., April 16, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identify [Read more]